Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Curr Opin Allergy Clin Immunol. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
PMCID: PMC2832909

Asthma and Chronic Obstructive Pulmonary Disease

Natural History, Phenotypes, and Biomarkers


Purpose of the review

In the clinical setting, patients who present with a combination of asthma and chronic obstructive pulmonary disease (COPD) related traits are not uncommon. This review discusses recent advances in the characterization of the natural course, phenotypes, and molecular markers of cases with co-existing asthma and COPD and in the understanding of the nature of the link between these two conditions.

Recent findings

Recent epidemiological evidence indicates that asthma accounts for a substantial proportion of cases of irreversible airflow limitation in the general population and that, in addition to the critical role of environmental exposures in adult age, alterations of developmental processes in childhood may also predispose subjects with asthma to COPD later in life. Findings from clinical and experimental studies emphasize the existence of remarkable heterogeneity within the group of subjects with co-existing asthma and COPD in terms of natural history of lung function, risk factors for disease progression, lung structural changes, and immunological profiles.


The phenotypic complexity of cases with co-existing asthma and COPD challenges a rigid categorization of patients into existing diagnostic labels and suggests the importance of integrating clinical, functional, morphologic, immunological, and molecular assessments to tailor and optimize prevention and treatment.

Keywords: asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema


Asthma and COPD are considered distinct obstructive lung diseases, with different diagnostic and management strategies(13). Yet, in the clinical setting patients who present with a combination of asthma- and COPD-related phenotypes are not uncommon. Understanding the natural history, risk factors, and molecular pathways involved in these cases of overlapping disease may have critical implications not only for their prevention and treatment, but also for a better comprehension of the links between these conditions. Nearly fifty years ago, Orie and colleagues(4) proposed in what would be later dubbed the “Dutch hypothesis” that asthma and COPD should be considered different expressions of one disease entity. Since then, much debate has taken place in the scientific community and multiple studies have over time emphasized the similarities between these “phenotypes” or the differences between these “diseases”. Although the nature of the link between asthma and COPD has not been conclusively resolved, these studies have produced considerable advance in our knowledge as they have progressively applied more homogeneous clinical definitions and more refined functional, morphologic, immunological, and in recent times genomic and proteomic assessments. This review discusses the significant progress made on this subject in the last few years, with a particular focus on studies that were published since January 2008.


Much of the difficulty in distinguishing asthma, chronic bronchitis, emphysema, and COPD originates from the fact that their working definitions are not mutually exclusive and are differentially based on clinical, functional, and anatomic criteria. For example, the Global Initiative for Asthma (GINA) has proposed an operational definition of asthma based on the presence of airway inflammation, respiratory symptoms, reversible airflow limitation, and bronchial hyperresponsiveness(1). In contrast, the two traditional main sub-phenotypes of COPD are defined either clinically (chronic bronchitis: cough and phlegm production for three months in at least two consecutive years)(5) or anatomically (emphysema: permanent enlargement of the airspaces distal to the terminal bronchioles)(5). Furthermore, the most widely used definition of COPD, which was established by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), emphasizes the importance of the functional assessment of usually progressive, non-fully reversible airflow limitation(2, 3), measured as a ratio between forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) after bronchodilator below 0.7.

The unifying definition of COPD by the GOLD guidelines has been largely adopted by the research community and has enhanced substantially comparability across different studies on COPD in the last ten years. In this context, two methodological issues need to be briefly discussed here, as they can affect the extent of the phenotypic overlap between asthma and COPD. First, because the FEV1/FVC ratio declines with age, using the fixed cut-off of 0.7 for all ages – despite its practical advantages – will underestimate the prevalence of the disease in young adults and overestimate it in older subjects(68). Similarly, it may under-diagnose the disease among women because females on average have higher FEV1/FVC ratios than males. The ATS/ERS guidelines on lung function(9) have proposed the alternative use of lower limits of normal (LLN) to define airflow limitation, which should remove age- and sex-related effects. Several recent multi-center studies have provided findings in support of this approach(68). In one of them(6•), among 20-to-44-years-old participants in the European Community Respiratory Health Survey less than 50% of subjects with airflow obstruction by LLN met the GOLD criteria for COPD, suggesting that, by using the GOLD definition, the majority of cases of airflow limitation would be missed in a young population. Because asthma is frequent among young adults and women, defining airflow limitation based on LLN instead of the fixed 0.7 cut-off might result in a larger number of asthma cases being identified as having co-existing COPD.

However, these observations should be interpreted with caution in light of a second methodological issue: the GOLD criteria are based on lung function after bronchodilator, whereas the majority of epidemiological studies on this subject did not include reversibility testing and, therefore, used only pre-bronchodilator lung function. This is not a secondary issue. Data from the Burden of Obstructive Lung Disease study showed that administration of 200 μg of albuterol reduced COPD estimates by 25% in the general population(7•) and this bronchodilator effect may be stronger in young as compared with older adults(10). Given the key role of reversible airflow limitation in asthma, one would expect that using post--bronchodilator lung function will resolve airflow limitation preferentially among asthmatics and will, in turn, reduce the proportion of COPD cases associated with asthma. However, to what extent this is the case remains to be determined(11).


That asthma, chronic bronchitis, emphysema, and COPD are frequently reported (in different combinations) by the same subjects has been long known and effectively illustrated in epidemiological studies using the proportional Venn diagram(1214). In one of these studies(14•) (Figure 1), using phenotypic data that also included post-bronchodilator lung function and chest CT scans the authors found that more than one third of subjects with COPD had never smoked and that asthma accounted for more than 50% of COPD cases both among smokers and never smokers. The hypothesis that asthma may have a key, or at least contributing, role in the development of a substantial proportion of COPD cases in the general population is consistent with previous prospective studies that found active asthma to increase the risk of acquiring a subsequent label of COPD by 8 to 12 times(15, 16).

Figure 1
Proportional Venn diagram depicting the overlap of asthma, chronic bronchitis, emphysema, and COPD in the Wellington Respiratory Survey

In this context, it is noteworthy that the co-existence of asthma and COPD appears to identify cases with particularly elevated severity(12), mortality risk(17), and economic burden(18, 19). In a large Medicaid database, cases with co-existing diagnoses of asthma and COPD had an average annual medical cost that was six times higher than that of asthma cases and three times higher than that of COPD cases(18). The increased disease severity shown by subjects with multiple obstructive lung diseases is also suggested by a recent cluster analysis on a group of 175 well-characterized subjects with current respiratory symptoms and/or airflow obstruction(20••). One of the five clusters that were identified included subjects with co-existing signs of asthma (reversibility and atopy), chronic bronchitis (sputum production), and emphysema (reduced DLCO, hyperinflation, and macroscopic emphysema on CT scanning). This cluster had the most severe disease based on degree of airflow limitation, hospital admissions, and prescribed treatment. However, it only accounted for 10% of participants and was mainly composed of heavy smokers, suggesting that this cluster might capture only a subgroup of particularly susceptible cases in which the effects of asthma and smoking operate synergistically. This is only one of the many observations (reviewed in the next sections) that support the existence of significant phenotypic heterogeneity not only among patients labeled with the single entities of asthma or COPD(21, 22) (23•), but also within the group of patients with co-existing asthma and COPD.

Natural History

In light of the above observations, understanding the natural history of cases that develop COPD as a sequela of (or in association with co-existing) asthma represents a research priority. In terms of lung function, in principle there are at least three mechanisms through which any subject (with or without asthma) can develop impaired levels in adulthood: an incomplete growth of lung function in childhood, an early start of its decline after the plateau phase, or an acceleration of lung function decline in adult age (or any combination of these mechanisms). A recent report from the Tucson Epidemiological Study of Airway Obstructive Disease (TESAOD)(24) has addressed the question of which of these mechanisms is mainly at work in asthmatics vs. non-asthmatics who develop persistent airflow limitation (as a hallmark of COPD). Results indicated that, whereas subjects without asthma develop COPD mainly as a consequence of an accelerated decline of lung function usually associated with cigarette smoking, among subjects who develop COPD following persistent childhood asthma the bulk of lung function impairment is already established by young adulthood (Figure 2). These findings are consistent with other long-term longitudinal studies(2528) that have shown strong tracking of lung deficits associated with childhood asthma into adolescence and up to mid-adult life. Taken together, these observations are compatible with a scenario in which the inter-play between genetic predisposition and environmental exposures (including viral infections and key signals for immune maturation) in childhood may impact key developmental processes and in turn predispose susceptible asthmatics to development of COPD many years later(2931). Indeed, some of these genetic and environmental influences might already take place in utero(29••), as being in the lowest quartile of airway function shortly after birth was found to be associated with a mean 5% deficit in FEV1/FVC throughout the period from age 11 years up to age 22(32).

Figure 2
Natural history of lung function among participants in the TESAOD Study

The above considerations should not underplay by any means the influence of environmental exposures in adult life on risk and natural course of these conditions, first and foremost cigarette smoking and occupational hazards, whose removal is still the single most important preventive intervention in COPD. Nor should they be interpreted as evidence that asthma is in no case associated with an accelerated decline of lung function. In fact, some epidemiological studies have found a faster FEV1 decline among adults with asthma as compared with subjects with no asthma(33, 34) and also in the above mentioned TESAOD study(24) the subgroup of subjects with adult-onset asthma developed persistent airflow limitation by means of both moderate FEV1 deficits in young adulthood and accelerated FEV1 decline thereafter. Clinical studies have shown that, in patients with asthma, this accelerated decline of lung function is related to bronchial CD8+ cell infiltrates(35), airway neutrophilic inflammation(36), and the frequency of acute exacerbations(37) (38•).

Thus, the natural history of lung function through which subjects with asthma develop COPD may be different depending on the age at onset of disease and the sub-type of asthma.

Lung Structural Changes

By now, it should be clear why biomarkers – in their broad sense of objectively measured characteristics that can be used as an indicator of pathogenic processes or responses to therapeutic interventions(39) – represent one of the most active areas of research in obstructive lung disease.

Among such objective characteristics is the assessment of airway remodeling, which may be responsible for part of the phenotypic overlap between asthma and COPD. However, the lung structural changes that take place in these conditions are considerably different(40) (41•). For example, alveolar parenchyma destructive alterations (the hallmark of emphysema) are mostly found in COPD. In contrast, increased airway smooth muscle mass, a key determinant of bronchial hyperresponsiveness, is mainly related to asthma and among asthmatics it is remarkably associated with severity of disease and the presence of airflow limitation(42) (43••), even early in childhood(44•). Similarly, the degree(42, 45) and composition(46) of thickening of the airway reticular basement membrane appear able to differentiate asthma from COPD, although the relation of this feature of airway remodeling to asthma severity remains somewhat controversial(42, 43, 45). Interestingly, even among asthmatics with COPD-like neutrophilic inflammation, high resolution CT (HRCT) scan emphysema score was lower but the bronchial wall thickening greater than in patients with traditional COPD(47•).

Thus, the development of persistent airway obstruction in subgroups of asthmatics might be characterized by the degree of specific asthma-related features of airway remodeling. However, to what extent the assessment of the type and degree of lung structural changes can be used to guide classification and treatment of patients in the clinical setting remains unclear. This is a rapidly evolving area of research, which most likely will benefit from advances in less invasive technological tools, such as quantitative HRCT scanning(48).

Immunological Profiles

Important differences also exist in the immunological cells and mediators that are involved in asthma and COPD(49) (50••). Asthma is characterized by eosinophilic inflammation that is largely responsive to steroids, a predominance of CD4+ cells, release of Th-2 like mediators – such as IL-4, IL-5, IL-13 – and a main location of the pathological process in the proximal airways. In contrast, in COPD neutrophils, macrophages, and CD8+ cells play a major role and are responsible for much of the airway inflammation and lung damage, especially in the small airways, with release of pro-inflammatory cytokines and chemokines, such as IL-6, IL-8, IL-1β, TNF-α.

These differences become less clear when cases of severe asthma are compared with COPD. Findings from several studies support the hypothesis that severe asthma has an immunological profile that resembles to some extent that found in COPD, with a predominance of neutrophilic inflammation(47, 5054), larger involvement of CD8+ T cells(35), and higher IL-8 mRNA levels in sputum(55). However, an alternative and equally extensive body of evidence indicates that the degree of traditional asthma-related phenotypes – such as eosinophilic inflammation, atopic sensitization, and serum IgE levels – can play a direct role in the development of persistent airflow limitation(24, 5659).

Thus, it appears that subjects with asthma can develop severe disease, non-fully reversible airflow limitation, and COPD both in association with particularly severe degrees of asthma-related lung structural changes and eosinophilic inflammation; and in combination with the co-occurrence of COPD-related inflammatory patterns. The former pathway may be mainly at work among cases with asthma onset in childhood and the latter among cases with adult-onset asthma or overlying exposure to cigarette smoking. Consistent with the existence of multiple pathways, both levels of airway neutrophils and atopic sensitization were independent predictors of air trapping in the Severe Asthma Research Program(60•) and increases in both blood eosinophils and blood neutrophils were associated with decreases in FEV1 values and risk of COPD-like symptoms, respectively, in the French EGEA study(61•).

To illustrate even further the dynamic nature of the relation between these conditions, the co-occurrence of asthma-like phenotypes in patients with COPD is also possible. For example, eosinophilic airway inflammation is found in a sub-group of patients with COPD, among whom it is associated with increased levels of the Th-2 like cytokine IL-5, some degree of reversibility of airflow limitation, increased exhaled nitric oxide, and a better response to pharmacological treatment with steroids(22, 6265), all features that resemble asthma-like phenotypes.

In Search of Genetic and Molecular Biomarkers

The above observations point towards the complexity of the phenotypic heterogeneity of cases with co-existing asthma and COPD and reinforce the importance of searching for new genetic and molecular biomarkers to identify homogeneous subgroups of patients in terms of etiologic mechanisms and response to treatment. Although to date most studies on molecular biomarkers of asthma and COPD – reviewed elsewhere(6670) – have focused on one disease at a time, some of their findings have important implications on our understanding of molecular pathways involved in cases with co-existing diseases.

For example, several genes originally identified for asthma have been subsequently found to be also associated with COPD-like phenotypes(71) and may be involved in the link between these two diseases. The case of a disintegrin and metalloprotease 33 (ADAM33) is illustrative. First identified as an asthma and bronchial hyperresponsiveness gene via positional cloning(72), ADAM33 has been later associated with decline of lung function and COPD susceptibility in the general population(73, 74). The possible involvement of this gene in cases of progression of asthma into COPD-like phenotypes is also supported by the observations that genetic variation in ADAM33 predicts accelerated decline of lung function among asthmatics(75) and that bronchoalveolar lavage levels of its soluble form – which has been shown to have potential tissue remodeling properties(76) – are strongly correlated with severity of asthma, as measured by levels of FEV1 % predicted(77).

The existence of shared molecular markers in subgroups of patients with asthma and COPD is also suggested by studies measuring concentrations of molecules in serum/plasma. For example, differentiation of asthma from COPD using serum inflammatory markers has proved challenging(78, 79) and serum levels of C-reactive protein (CRP), which are known to be elevated in patients with COPD(69), have been also found to be increased among patients with non-atopic asthma(80, 81). These findings could underline the existence of shared inflammatory pathways or simply reflect the “unspecific” nature of inflammatory markers, such as CRP, that may be elevated in response to multiple conditions and/or environmental exposures. To overcome such limitation, a related line of research is focusing on identifying molecules in blood that are produced mostly in the lungs and thus may be specifically linked to pulmonary disease(82) or that are specifically associated with well-known pathogenic processes involved in asthma or COPD(83•). This approach might also be more effective in discriminating between the two diseases(83).

The public health and clinical impact of biomarker research in asthma and COPD to date has been also limited by the cross-sectional nature of most molecular studies, which has precluded resolution of whether concentrations of the biomarker in biofluids are elevated as a cause or a consequence of the disease. Most likely, the use of prospective study designs and the integration of information from both biomarker concentrations in fluids and variation in their encoding genes(84) (85••) (86•) will be important elements to resolve directionality in biomarker ↔ disease associations and minimize residual confounding and bias in future studies. Also, the increasing use of large multiplex biomarker panels(43), genomics(8789) and proteomics(90, 91) techniques will facilitate exploration of new molecular pathways, with the goals of capturing interactive effects between multiple genes, molecules, and environmental exposures and identifying novel biomarkers that may be specifically linked to cases with asthma, cases with COPD, or cases at risk for the combination of these conditions.


In conclusion, findings from recent studies emphasize the frequency and clinical impact of the overlap between asthma and COPD and the considerable phenotypic heterogeneity of cases with co-existing diseases. This complexity challenges a rigid categorization of patients into existing diagnostic labels of either asthma or COPD and suggests the importance of multiple clinical, functional, morphologic, immunological, and molecular assessments that can be used to tailor and optimize treatment and prevention of subjects with (or at risk of) these diseases. Moving towards such an integrated approach will certainly require time, but the phenotypic characterization and the exploration of the genetic and molecular components of these diseases are now progressing to an unprecedented pace, with the promise of generating soon more effective preventive and diagnostic profiles.


This work was supported in part by grant HL085195 by the National Heart, Lung, and Blood Institute


Dr Guerra is the recipient of a Parker B. Francis Fellowship.


1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (updated 2008) Available from:
2. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (updated 2008) Available from:
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532–55. [PubMed]
4. Orie NGM, Sluiter HJ, de Vries K, Tammeling GJ, Witkop J. The host factor in bronchits. In: Orie NGM, Sluiter HJ, editors. Bronchitis an international symposium. Assen, Netherlands: Royal vanGorcum; 1961.
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 2):S77–121. [PubMed]
6* Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, Anto JM, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax. 2008 Dec;63(12):1040–5. This study uses data from the European Community Respiratory Health Survey to demonstrate that, in a cohort of 20 to 44 years old subjects, using the GOLD definition of COPD misses more than half of cases with FEV1/FVC ratio below lower limits of normal and that this under-diagnosis of airflow obstruction affects mainly young adults and women. [PubMed]
7* Vollmer WM, Gislason T, Burney P, Enright PL, Gulsvik A, Kocabas A, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD Study. Eur Respir J. 2009 May 21; Using data from more than 10,000 participants in the international Burden of Obstructive Lung Disease study, this report demonstrates that defining COPD by FEV1/FVC below the lower limit of normal reduces substantially the age-related increase in COPD prevalence among healthy never smokers and that using values after (instead of before) bronchodilator impacts substantially estimates of prevalence of COPD in the general population. [PMC free article] [PubMed]
8. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008 Dec;63(12):1046–51. [PubMed]
9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948–68. [PubMed]
10. Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A, et al. COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007 Aug;30(2):232–9. [PMC free article] [PubMed]
11. Perez-Padilla R, Hallal PC, Vazquez-Garcia JC, Muino A, Maquez M, Lopez MV, et al. Impact of bronchodilator use on the prevalence of COPD in population-based samples. Copd. 2007 Jun;4(2):113–20. [PubMed]
12. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003 Aug;124(2):474–81. [PubMed]
13. Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest. 2004 Oct;126(4):1093–101. [PubMed]
14* Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, et al. Proportional classifications of COPD phenotypes. Thorax. 2008 Sep;63(9):761–7. An epidemiological study addressing the overlap of asthma, chronic bronchitis, emphysema, and COPD in a sample from the general population in New Zealand. The phenotypic characterization of participants, which includes post-bronchodilator lung function and CT scans, is the main strength of the study. [PMC free article] [PubMed]
15. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a Risk Factor for COPD in a Longitudinal Study. Chest. 2004 Jul;126(1):59–65. [PubMed]
16. Galobardes B, McCarron P, Jeffreys M, Davey Smith G. Association between early life history of respiratory disease and morbidity and mortality in adulthood. Thorax. 2008 May;63(5):423–9. [PubMed]
17. Meyer PA, Mannino DM, Redd SC, Olson DR. Characteristics of adults dying with COPD. Chest. 2002 Dec;122(6):2003–8. [PubMed]
18. Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DW, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008 Jul;134(1):14–9. [PubMed]
19. Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm. 2008 Mar;14(2):176–85. [PubMed]
20** Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, Nowitz MR, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009 Apr 8; In a random population sample of 25 to 75 years old subjects, the authors of this report found that individuals with airflow limitation and/or respiratory symptoms could be grouped into five main clusters. Results provide important insights on how different asthma- and COPD-related phenotypes are distributed in the general population. [PubMed]
21. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 1;178(3):218–24. [PubMed]
22. Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. COPD phenotype description using principal components analysis. Respir Res. 2009 May 29;10(1):41. [PMC free article] [PubMed]
23* Patel BD, Coxson HO, Pillai SG, Agusti AG, Calverley PM, Donner CF, et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Sep 1;178(5):500–5. A report from the multicenter International COPD Genetics Network demonstrating that high resolution CT scan-identified airway wall thickening and emphysema show independent aggregation within families. Results suggest that different genetic determinants may be involved in these two phenotypes. [PubMed]
24. Guerra S, Sherrill DL, Kurzius-Spencer M, Venker C, Halonen M, Quan SF, et al. The course of persistent airflow limitation in subjects with and without asthma. Respir Med. 2008 Oct;102(10):1473–82. [PMC free article] [PubMed]
25. Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al. Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence. Am J Respir Crit Care Med. 2005 Nov 15;172(10):1253–8. [PMC free article] [PubMed]
26. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003 Oct 9;349(15):1414–22. [PubMed]
27. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964–1999. J Allergy Clin Immunol. 2002 Feb;109(2):189–94. [PubMed]
28. Marossy AE, Strachan DP, Rudnicka AR, Anderson HR. Childhood chest illness and the rate of decline of adult lung function between ages 35 and 45 years. Am J Respir Crit Care Med. 2007 Feb 15;175(4):355–9. [PubMed]
29** Martinez FD. The origins of asthma and chronic obstructive pulmonary disease in early life. Proc Am Thorac Soc. 2009 May 1;6(3):272–7. An insightful perspective of the importance of developmental alterations early in life that may predispose susceptible subjects to asthma and COPD years later. [PMC free article] [PubMed]
30. Holt PG, Sly PD. Non-atopic intrinsic asthma and the ‘family tree’ of chronic respiratory disease syndromes. Clin Exp Allergy. 2009 Apr 21; [PubMed]
31. Bush A. COPD: a pediatric disease. Copd. 2008 Feb;5(1):53–67. [PubMed]
32. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet. 2007 Sep 1;370(9589):758–64. [PMC free article] [PubMed]
33. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998 Oct 22;339(17):1194–200. [PubMed]
34. James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005 Jan 15;171(2):109–14. [PubMed]
35. van Rensen EL, Sont JK, Evertse CE, Willems LN, Mauad T, Hiemstra PS, et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med. 2005 Oct 1;172(7):837–41. [PubMed]
36. Boulet LP, Turcotte H, Turcot O, Chakir J. Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med. 2003 Jun;97(6):739–44. [PubMed]
37. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007 Sep;30(3):452–6. [PubMed]
38* O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009 Jan 1;179(1):19–24. A recent study that confirms the previously reported association between asthma exacerbations and decline of lung function. [PubMed]
39. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89–95. [PubMed]
40. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J. 2007 Jul;30(1):134–55. [PubMed]
41* Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008 Jan;14(1):31–8. A thorough review of lung structural alterations associated with asthma and COPD. [PubMed]
42. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med. 2003 May 15;167(10):1360–8. [PubMed]
43** Kaminska M, Foley S, Maghni K, Storness-Bliss C, Coxson H, Ghezzo H, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol. 2009 May 28; In this study, patients with asthma associated with persistent airflow limitation were characterized extensively in terms of their inflammatory profiles, airway remodeling, and imaging, and their characteristics were compared to those of subjects with milder asthma. Severe asthma was found to be associated with more inflammatory cells in sputum, greater smooth muscle area, and both Th1 and Th2 inflammatory responses. [PubMed]
44* Tillie-Leblond I, de Blic J, Jaubert F, Wallaert B, Scheinmann P, Gosset P. Airway remodeling is correlated with obstruction in children with severe asthma. Allergy. 2008 May;63(5):533–41. This study demonstrates that structural abnormalities, such as increases in surface area of airway smooth muscle and number of vessels, are present in children with asthma associated with airway obstruction, suggesting that airway remodeling can be already present in childhood among cases of severe persistent asthma. [PubMed]
45. Bourdin A, Neveu D, Vachier I, Paganin F, Godard P, Chanez P. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol. 2007 Jun;119(6):1367–74. [PubMed]
46. Liesker JJ, Hacken NH, Zeinstra-Smith M, Rutgers SR, Postma DS, Timens W. Reticular basement membrane in asthma and COPD: Similar thickness, yet different composition. Int J Chron Obstruct Pulmon Dis. 2009;4(1):127–35. [PMC free article] [PubMed]
47* Simpson JL, Milne DG, Gibson PG. Neutrophilic asthma has different radiographic features to COPD and smokers. Respir Med. 2009 Jun;103(6):881–7. In this clinical study, patients with neutrophilic asthma were compared with subjects with traditional COPD. Despite comparable levels of airflow limitation, the former had greater bronchial wall thickening and lower emphysema score (assessed by HRCT) than did subjects with COPD. These results suggest that, even in the presence of neutrophilic inflammation, the radiographic features of asthma are distinguishable from those associated with COPD. [PubMed]
48. Grydeland TB, Dirksen A, Coxson HO, Pillai SG, Sharma S, Eide GE, et al. Quantitative CT: Emphysema and airway wall thickness by gender, age and smoking. Eur Respir J. 2009 Mar 26; [PubMed]
49. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol. 2003 Nov;112(5):819–27. quiz 28. [PubMed]
50** Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008 Mar;8(3):183–92. An insightful review of the immunological cells, mediators, and mechanisms involved in asthma and COPD. [PubMed]
51. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1532–9. [PubMed]
52. Jang AS, Lee JH, Park SW, Park JS, Kim DJ, Park CS. Risk factors related to fixed airway obstruction in patients with asthma after antiasthma treatment. Ann Allergy Asthma Immunol. 2007 Nov;99(5):408–12. [PubMed]
53. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007 Dec;132(6):1882–9. [PubMed]
54. Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007 Dec;132(6):1871–5. [PubMed]
55. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006;7:135. [PMC free article] [PubMed]
56. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001 Sep 1;164(5):744–8. [PubMed]
57. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J. 2004 Jul;24(1):122–8. [PubMed]
58. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Feb 1;167(3):418–24. [PubMed]
59. Di Lorenzo G, Mansueto P, Ditta V, Esposito-Pellitteri M, Lo Bianco C, Leto-Barone MS, et al. Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease. Respir Med. 2008 Feb;102(2):232–8. [PubMed]
60* Busacker A, Newell JD, Jr, Keefe T, Hoffman EA, Granroth JC, Castro M, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009 Jan;135(1):48–56. This study focuses on independent predictors for development of air trapping, a phenotype that identifies asthmatics at high risk of severe disease and airflow limitation, using the clinical cohort of the Severe Asthma Research Program. [PMC free article] [PubMed]
61* Nadif R, Siroux V, Oryszczyn MP, Ravault C, Pison C, Pin I, et al. Heterogeneity of asthma according to blood inflammatory patterns. Thorax. 2009 May;64(5):374–80. An interesting report from the French Epidemiological Study on the Genetics and Environment of Asthma, in which clinical characteristics of asthmatics were compared based on the combination of low versus high eosinophil and neutrophil counts in blood. [PubMed]
62. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, et al. Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPD. Respiration. 2009 May 27; [PMC free article] [PubMed]
63. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007 May;29(5):906–13. [PubMed]
64. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005 Mar;60(3):193–8. [PMC free article] [PubMed]
65. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Nov;162(5):1773–7. [PubMed]
66. Guerra S, Martinez FD. Asthma genetics: from linear to multifactorial approaches. Annu Rev Med. 2008;59:327–41. [PubMed]
67. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008 Mar;8(3):169–82. [PubMed]
68. Marciniak SJ, Lomas DA. What can naturally occurring mutations tell us about the pathogenesis of COPD? Thorax. 2009 Apr;64(4):359–64. [PubMed]
69. Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol. 2008 Jun;8(3):222–35. [PubMed]
70. Taylor DR, Pavord ID. Biomarkers in the assessment and management of airways diseases. Postgrad Med J. 2008;84(998):628–34. quiz 33. [PubMed]
71. Meyers DA, Larj MJ, Lange L. Genetics of asthma and COPD. Similar results for different phenotypes. Chest. 2004 Aug;126(2 Suppl):105S–10S. discussion 59S–61S. [PubMed]
72. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002 Jul 25;418(6896):426–30. [PubMed]
73. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Boezen HM. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med. 2005 Aug 1;172(3):329–33. [PubMed]
74. Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, et al. Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res. 2009;10:21. [PMC free article] [PubMed]
75. Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy. 2004 May;34(5):757–60. [PubMed]
76. Puxeddu I, Pang YY, Harvey A, Haitchi HM, Nicholas B, Yoshisue H, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol. 2008 Jun;121(6):1400–6. 6 e1–4. [PubMed]
77. Lee JY, Park SW, Chang HK, Kim HY, Rhim T, Lee JH, et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: Relevance to airflow limitation. Am J Respir Crit Care Med. 2006 Apr 1;173(7):729–35. [PubMed]
78. Hollander C, Sitkauskiene B, Sakalauskas R, Westin U, Janciauskiene SM. Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir Med. 2007 Sep;101(9):1947–53. [PubMed]
79. Higashimoto Y, Yamagata Y, Taya S, Iwata T, Okada M, Ishiguchi T, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences. Respirology. 2008 Jan;13(1):128–33. [PubMed]
80. Olafsdottir IS, Gislason T, Thjodleifsson B, Olafsson I, Gislason D, Jogi R, et al. C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax. 2005 Jun;60(6):451–4. [PMC free article] [PubMed]
81. Butland BK, Strachan DP, Rudnicka AR. C-reactive protein, obesity, atopy and asthma symptoms in middle-aged adults. Eur Respir J. 2008 Jul;32(1):77–84. [PubMed]
82. Sin DD, Pahlavan PS, Man SF. Surfactant protein D: a lung specific biomarker in COPD? Ther Adv Respir Dis. 2008 Apr;2(2):65–74. [PubMed]
83* O’Reilly P, Jackson PL, Noerager B, Parker S, Dransfield M, Gaggar A, et al. N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir Res. 2009 May 18;10(1):38. An interesting report that proposes two tri-peptides, N-alpha-PGP and PGP, which are collagen fragments related to the action of matrix metalloproteases, as useful biomarkers to identify subjects with (or at risk of) COPD and differentiate them from asthmatics. PGP was measured both in sputum and in serum. [PMC free article] [PubMed]
84. Schunkert H, Samani NJ. Elevated C-reactive protein in atherosclerosis--chicken or egg? N Engl J Med. 2008 Oct 30;359(18):1953–5. [PubMed]
85** Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008 Apr 17;358(16):1682–91. In this study, the authors demonstrated associations between serum levels of the chitinase-like protein YKL-40, a novel biomarker for asthma, and both variation in its encoding gene CHI3L1 and asthma status. They also found a single nucleotide polymorphism in the CHI3L1 gene to be associated with asthma risk, bronchial hyperresponsiveness, and lung function. Triangulation among protein concentrations, variation in their encoding genes, and phenotype of interest is a particularly strong study design to explore causal relations in biomarker research. [PMC free article] [PubMed]
86* van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottelberge GR, Hofman A, Witteman JC, et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Mar 1;179(5):375–82. In this large prospective study, CRP levels at baseline were significantly associated with development of incident COPD over the study follow-up. Despite variation in the CRP gene was related to CRP levels, it was not associated with COPD risk. Findings from this and other studies may question a directly causal relation of CRP to risk of COPD and ischemic heart disease. [PubMed]
87. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007 Jul 26;448(7152):470–3. [PubMed]
88. Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P, Strachan DP, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet. 2009 May;84(5):581–93. [PubMed]
89. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009 Mar;5(3):e1000421. [PMC free article] [PubMed]
90. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med. 2008 Sep 1;178(5):444–52. [PMC free article] [PubMed]
91. Casado B, Iadarola P, Luisetti M, Kussmann M. Proteomics-based diagnosis of chronic obstructive pulmonary disease: the hunt for new markers. Expert Rev Proteomics. 2008 Oct;5(5):693–704. [PubMed]